Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics Inc. - Class A Common Shares (NQ:CRDL)

1.305 -0.065 (-4.74%)
Streaming Delayed Price Updated: 10:00 AM EDT, Apr 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 115,094
Open 1.360
Bid (Size) 1.300 (600)
Ask (Size) 1.310 (1,100)
Prev. Close 1.370
Today's Range 1.280 - 1.370
52wk Range 0.8800 - 1.710
Shares Outstanding 65,352,279
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)
Via Get News
Topics Intellectual Property
News headline image
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Via Get News
Topics Intellectual Property

Performance

YTD
+31.3%
+31.3%
1 Month
+7.0%
+7.0%
3 Month
+30.5%
+30.5%
6 Month
+11.5%
+11.5%
1 Year
+20.8%
+20.8%

More News

Read More
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Via PressReach
News headline image
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today ↗
Via Benzinga
News headline image
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Via Newsfile
News headline image
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Via PressReach
News headline image
This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Via Benzinga
News headline image
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Via Newsfile
News headline image
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Terry Lynch to Board, Grants Options
Via Investor Brand Network
News headline image
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart
Via Newsfile
News headline image
“Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”
Via AB Newswire
News headline image
3 Penny Stocks Ready to Break Out in 2025
Via MarketBeat
News headline image
Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!
Via AB Newswire
News headline image
“Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”
Via AB Newswire
Topics Economy
News headline image
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…
Via AB Newswire
News headline image
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study ↗
Via Benzinga
News headline image
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
Via AB Newswire
News headline image
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Via Newsfile
News headline image
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
Via AB Newswire
Topics Electric Vehicles
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
Via AB Newswire
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
Via AB Newswire
Topics Government
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
Via AB Newswire
Topics Intellectual Property
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
Via AB Newswire

Frequently Asked Questions

Is Cardiol Therapeutics Inc. - Class A Common Shares publicly traded?
Yes, Cardiol Therapeutics Inc. - Class A Common Shares is publicly traded.
What exchange does Cardiol Therapeutics Inc. - Class A Common Shares trade on?
Cardiol Therapeutics Inc. - Class A Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Cardiol Therapeutics Inc. - Class A Common Shares?
The ticker symbol for Cardiol Therapeutics Inc. - Class A Common Shares is CRDL on the Nasdaq Stock Market
What is the current price of Cardiol Therapeutics Inc. - Class A Common Shares?
The current price of Cardiol Therapeutics Inc. - Class A Common Shares is 1.305
When was Cardiol Therapeutics Inc. - Class A Common Shares last traded?
The last trade of Cardiol Therapeutics Inc. - Class A Common Shares was at 04/29/26 10:00 AM ET
What is the market capitalization of Cardiol Therapeutics Inc. - Class A Common Shares?
The market capitalization of Cardiol Therapeutics Inc. - Class A Common Shares is 85.28M
How many shares of Cardiol Therapeutics Inc. - Class A Common Shares are outstanding?
Cardiol Therapeutics Inc. - Class A Common Shares has 85M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.